Breast Cancer: Recurrent Genomic Alterations: Difference between revisions

[unchecked revision][unchecked revision]
mNo edit summary
mNo edit summary
Line 1: Line 1:
'''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
'''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Alteration'''
|'''Alteration'''
|'''Relevant Gene(s)'''
|'''Relevant Gene(s)'''
|'''CGC Evidence Level'''
|'''CGC Evidence Level'''
|'''Subgroup Association(s)'''
|'''Subgroup Association(s)'''
|-
|-
Line 71: Line 71:
|METABRIC IntClust1, ER Positive
|METABRIC IntClust1, ER Positive
|}
|}
Abbreviations: TNBC, triple negative breast cancer.
† See table below Table 2 for CGC Evidence levels


Abbreviations: TNBC, triple negative breast cancer; LOH, loss of heterozygosity.


'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Gene(s)'''
|'''Gene(s)'''
|'''CGC Evidence Level'''
|'''CGC Evidence Level'''
|'''Clinical Significance and Subgroup Association(s)'''
|'''Clinical Significance and Subgroup Association(s)'''
|'''Therapy Implication(s)'''
|'''Therapy Implication(s)'''
Line 234: Line 235:
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer.
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer.


'''Cancer Genomics Consortium Levels of Evidence'''
'''Cancer Genomics Consortium Levels of Evidence'''
{| class="wikitable"
{| class="wikitable"
|'''Tier'''
|'''Tier'''
Line 258: Line 259:




'''Table 3 - Genes with known hereditary risk associations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
'''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Gene'''
|'''Gene'''